US 11,850,266 B2
Cardiomyocytes and compositions and methods for producing the same
Richard T. Lee, Cambridge, MA (US); Jessica Garbern, Brookline, MA (US); Douglas A. Melton, Cambridge, MA (US); and Aharon Helman, Cambridge, MA (US)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US); and The Children's Medical Center Corporation, Boston, MA (US)
Appl. No. 17/616,994
Filed by President and Fellows of Harvard College, Cambridge, MA (US); and The Children's Medical Center Corporation, Boston, MA (US)
PCT Filed Jun. 8, 2020, PCT No. PCT/US2020/036709
§ 371(c)(1), (2) Date Dec. 6, 2021,
PCT Pub. No. WO2020/247957, PCT Pub. Date Dec. 10, 2020.
Claims priority of provisional application 62/933,962, filed on Nov. 11, 2019.
Claims priority of provisional application 62/884,592, filed on Aug. 8, 2019.
Claims priority of provisional application 62/858,302, filed on Jun. 6, 2019.
Prior Publication US 2022/0354899 A1, Nov. 10, 2022
Int. Cl. A61K 35/34 (2015.01); A61K 38/00 (2006.01); A61P 9/00 (2006.01)
CPC A61K 35/34 (2013.01) [A61K 38/005 (2013.01); A61P 9/00 (2018.01)] 18 Claims
OG exemplary drawing
 
1. A method of producing a mature cardiomyocyte from an immature cardiomyocyte comprising contacting the immature cardiomyocyte with an mTOR inhibitor after the immature cardiomyocyte begins beating and/or after the immature cardiomyocyte begins expressing at least one of troponin T, troponin I, myosin heavy chain 6, or myosin heavy chain 7, and wherein the mature cardiomyocyte exhibits increased expression of REST and/or GATA4 as compared to an immature cardiomyocyte.